Purchase this article with an account.
M. Tanaka, M. Dogru, Y. Takano, N. Asano–Kato, K. Fukagawa, K. Tsubota, H. Fujishima; Long–Term Results of Mitomycin–C (mmc)–Aided Papillary Resection in Patients With Severe Ocular Allergies . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4979.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the long–term outcomes of MMC–aided papillary resection in patients with severe ocular allergies.
Subjects were cases of atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) with corneal lesions refractory to conventional treatments. Mitomycin–aided papillary resection with 0.02% (7 eyes) or 0.05% (28 eyes) was performed in these patients. Recurrence of corneal lesions were compared between the two concentrations of MMC. The follow up period was from 2 years to 5 years postoperatively.
Corneal lesions swiftly healed in both groups. Short term recurrence (within 6 months) was inhibited in both groups. However, exacerbations within 2 years were less in the 0.05% group compared to the 0.02% group (32.1%, 71.4% respectively). No complications related to MMC use were observed in either group.
Both 0.02% and 0.05% MMC–aided papillary resection were found to be effective in the treatment of severe ocular allergies complicated by corneal lesions. However, 0.05%MMC was more effective in preventing long–term exacerbations.
This PDF is available to Subscribers Only